Physician profile
Robert Pyle
NPI 1821007253
$2,702.44
in general payments reported to CMS, 2019-2025
10 companies · $357 in 2025
The $357 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $286 · 2021: $651 · 2022: $297 · 2023: $399 · 2024: $177 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $911.70 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $640.29 | 2019-2022 | |
| Amgen INC. | $446.19 | 2019-2021 | |
| Medtronic, INC. | $429.23 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $414.89 | 2021-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $242.63 | 2021-2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $214.90 | 2021-2022 | |
| Rgh Enterprises LLC | $96.00 | 2025 | |
| Medtronic Minimed, INC. | $76.94 | 2019-2020 | |
| Shire North American Group INC | $70.92 | 2019 | |
| Lilly USA, LLC | $70.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.